Core Viewpoint - Old Dominion Freight Line, Inc. (ODFL) is currently facing multiple challenges that make it an unattractive investment option [1] Earnings Estimates - The Zacks Consensus Estimate for ODFL's fourth quarter of 2025 earnings has decreased by 10.2% over the past 90 days, while the current year's earnings estimate has been revised downward by 1.2% in the same timeframe, indicating a lack of confidence from brokers [2] - For the fourth quarter of 2025, ODFL's earnings are expected to decline by 13.82% year over year, and for the full year 2025, a decline of 12.23% year over year is anticipated [7] Price Performance - ODFL's shares have lost 8.4% over the past six months, contrasting with a 2.6% growth in the transportation-truck industry [4][6] Operational Challenges - The company is experiencing weak freight demand and ongoing supply chain issues, which have negatively impacted shipment volumes and rates, leading to a deterioration in the operating ratio from 72% in 2023 to 73.4% in 2024 despite cost-cutting efforts [8] - The trucking industry, including ODFL, is facing a persistent driver shortage, complicating recruitment as older drivers retire and younger generations show less interest in low-paying jobs [9] Industry Context - ODFL operates within an industry that has a Zacks Industry Rank of 194 out of 248 groups, placing it in the bottom 20% of Zacks industries, which suggests that the company's performance is heavily influenced by the overall industry conditions [10]

Company Performance - Prologis (PLD) shares decreased by 1.05% to $127.66, underperforming the S&P 500's loss of 0.74% [1] - Over the past month, Prologis shares appreciated by 0.06%, lagging behind the Finance sector's gain of 2.1% and the S&P 500's gain of 0.79% [1] Earnings Projections - Prologis is expected to report earnings of $1.44 per share on January 21, 2026, indicating a year-over-year decline of 4% [2] - The consensus estimate for revenue is projected at $2.1 billion, reflecting an 8.56% increase from the same quarter last year [2] - For the full year, earnings are projected at $5.8 per share and revenue at $8.17 billion, representing increases of 4.32% and 8.72% respectively from the prior year [3] Analyst Estimates and Valuation - Recent changes in analyst estimates for Prologis are crucial as they reflect short-term business dynamics, with upward revisions indicating positive sentiment towards the company's operations [4] - The Zacks Rank system, which assesses these estimate changes, currently ranks Prologis at 2 (Buy), with a recent upward shift of 0.02% in the consensus EPS estimate [6] - Prologis has a Forward P/E ratio of 22.23, which is a premium compared to the industry average of 11.07 [6] - The company has a PEG ratio of 3.96, higher than the industry average PEG ratio of 2.56 [7] Industry Context - The REIT and Equity Trust - Other industry, which includes Prologis, is currently ranked 78 in the Zacks Industry Rank, placing it in the top 32% of over 250 industries [7][8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Company Performance - Archer Daniels Midland (ADM) closed at $57.49, down 1.17% from the previous trading session, underperforming the S&P 500's loss of 0.74% [1] - Prior to the recent trading day, ADM shares had declined 3.55%, lagging behind the Consumer Staples sector's loss of 1% and the S&P 500's gain of 0.79% [1] Upcoming Earnings - ADM is projected to report earnings of $0.84 per share, reflecting a year-over-year decline of 26.32% [2] - Revenue is expected to be $22.14 billion, indicating a 2.98% increase compared to the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $3.4 per share, representing a decline of 28.27% from the prior year [3] - Revenue for the fiscal year is projected to be $83.85 billion, showing a decrease of 1.96% compared to the previous year [3] Analyst Estimates - Recent modifications to analyst estimates for ADM reflect changing short-term business dynamics, with positive changes indicating analyst optimism [4] - The Zacks Rank system, which incorporates these estimate changes, currently rates ADM as a 5 (Strong Sell) [6] Valuation Metrics - ADM has a Forward P/E ratio of 17.13, which is higher than the industry average of 16.34, suggesting it is trading at a premium [7] - The company has a PEG ratio of 4.95, compared to the industry average PEG ratio of 2.18, indicating a higher valuation relative to expected earnings growth [8] Industry Context - The Agriculture - Operations industry, part of the Consumer Staples sector, holds a Zacks Industry Rank of 220, placing it in the bottom 11% of over 250 industries [9] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [9]

Company Performance - Crocs (CROX) closed at $85.52, reflecting a -1.34% change from the previous day, which is less than the S&P 500's daily loss of 0.74% [1] - Over the past month, Crocs shares gained 1.68%, while the Consumer Discretionary sector and the S&P 500 gained 0.56% and 0.79%, respectively [1] Upcoming Earnings - Analysts expect Crocs to report earnings of $1.91 per share, indicating a year-over-year decline of 24.21% [2] - The consensus estimate for revenue is projected at $918.53 million, reflecting a 7.2% decrease from the same quarter last year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict earnings of $12.13 per share and revenue of $4 billion, representing declines of -7.9% and -2.45% from the previous year [3] - Recent changes to analyst estimates for Crocs indicate a dynamic nature of near-term business trends, with positive revisions suggesting analyst optimism [3] Valuation and Ranking - Crocs holds a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 7.15, which is a discount compared to the industry average Forward P/E of 17.86 [5] - The Zacks Rank system has a strong track record, with 1 stocks averaging an annual return of +25% since 1988 [5] Industry Context - The Textile - Apparel industry, part of the Consumer Discretionary sector, has a Zacks Industry Rank of 96, placing it in the top 39% of over 250 industries [6] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Company Performance - Kinsale Capital Group, Inc. (KNSL) closed at $391.12, reflecting a -1.14% change from the previous day, underperforming the S&P 500's daily loss of 0.74% [1] - Over the past month, KNSL shares have increased by 5.28%, while the Finance sector gained 2.1% and the S&P 500 rose by 0.79% [1] Upcoming Earnings - Analysts expect Kinsale Capital Group, Inc. to report earnings of $5.24 per share, indicating a year-over-year growth of 13.42% [2] - The consensus estimate for revenue is $471.37 million, which represents a 14.38% increase from the prior-year quarter [2] Full Year Projections - For the full year, Zacks Consensus Estimates project earnings of $18.9 per share and revenue of $1.86 billion, reflecting changes of +17.68% and +17.25% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Kinsale Capital Group, Inc. are important as they often reflect shifting business dynamics, with positive revisions indicating analyst optimism [4] Zacks Rank and Valuation - Kinsale Capital Group, Inc. currently holds a Zacks Rank of 3 (Hold), with the consensus EPS projection having moved 0.09% higher in the past 30 days [6] - The company is trading at a Forward P/E ratio of 20.93, which is a premium compared to the industry average Forward P/E of 11.51 [7] PEG Ratio - KNSL has a PEG ratio of 1.42, which is lower than the average PEG ratio of 1.67 for the Insurance - Property and Casualty industry [8] Industry Overview - The Insurance - Property and Casualty industry is part of the Finance sector and currently holds a Zacks Industry Rank of 45, placing it in the top 19% of over 250 industries [9]

Company Performance - Dynatrace (DT) closed at $43.34, down 1.72% from the previous trading session, underperforming the S&P 500, which fell by 0.74% [1] - The stock has decreased by 1.78% over the past month, while the Computer and Technology sector gained 0.14% and the S&P 500 increased by 0.79% [1] Earnings Projections - The upcoming EPS for Dynatrace is projected at $0.41, indicating a 10.81% increase year-over-year [2] - Quarterly revenue is estimated to be $505.77 million, reflecting a 15.96% increase from the same period last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $1.63 per share and revenue at $1.99 billion, representing increases of 17.27% and 17.21% respectively from the prior year [3] Analyst Estimates - Changes in analyst estimates for Dynatrace are crucial as they reflect short-term business trends and can influence stock performance [4] - Positive revisions in estimates indicate analysts' confidence in the company's performance and profit potential [4] Zacks Rank and Valuation - Dynatrace currently holds a Zacks Rank of 3 (Hold), with no changes in the consensus EPS estimate over the past month [6] - The company has a Forward P/E ratio of 27.02, which is higher than the industry average of 17.48 [7] - The PEG ratio for Dynatrace is 1.9, compared to the industry average PEG ratio of 1.82 [7] Industry Context - The Computers - IT Services industry, part of the Computer and Technology sector, has a Zacks Industry Rank of 78, placing it in the top 32% of over 250 industries [8] - Strong industry rankings correlate with stock performance, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [8]

Core Viewpoint - Rithm (RITM) is experiencing a decline in stock price and is expected to report lower earnings and revenue in the upcoming earnings release [1][2]. Group 1: Stock Performance - Rithm's stock closed at $10.90, reflecting a -1.54% change from the previous day's closing price, which is worse than the S&P 500's daily loss of 0.74% [1]. - Prior to the recent trading session, Rithm's shares had decreased by 2.29%, underperforming compared to the Finance sector's gain of 2.1% and the S&P 500's gain of 0.79% [1]. Group 2: Earnings Expectations - Rithm is anticipated to report an EPS of $0.54, which represents a 10% decrease from the same quarter last year [2]. - The consensus estimate for Rithm's revenue is $1.37 billion, indicating a significant decline of 34.89% from the prior-year quarter [2]. - For the full year, analysts expect earnings of $2.14 per share and revenue of $4.46 billion, reflecting changes of +1.9% and -14.84%, respectively, from the previous year [3]. Group 3: Analyst Forecasts and Valuation - Recent revisions to analyst forecasts for Rithm are important as they may indicate changes in near-term business trends, with positive revisions suggesting optimism about the business outlook [4]. - The Zacks Rank system, which evaluates estimate changes, currently ranks Rithm at 3 (Hold), with a consensus EPS projection that has decreased by 1.61% in the past 30 days [6]. - Rithm has a Forward P/E ratio of 5.18, which is a discount compared to the industry average Forward P/E of 12.09 [6]. Group 4: Industry Context - Rithm operates within the Financial - Miscellaneous Services industry, which is part of the Finance sector and currently holds a Zacks Industry Rank of 96, placing it in the top 39% of over 250 industries [7].

Company Performance - Medpace (MEDP) closed at $561.65, reflecting a -1.27% change from the previous day, underperforming the S&P 500's loss of 0.74% [1] - Prior to the latest trading session, Medpace shares had declined by 2.54%, contrasting with the Medical sector's loss of 0.8% and the S&P 500's gain of 0.79% [1] Earnings Forecast - Medpace is expected to report an EPS of $4.18, representing a 13.9% increase from the same quarter last year [2] - Revenue is forecasted to be $681.17 million, indicating a growth of 26.94% compared to the corresponding quarter of the prior year [2] Full Year Estimates - For the full year, analysts project earnings of $14.8 per share and revenue of $2.5 billion, reflecting increases of +17.18% and +18.68% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Medpace are important as they indicate shifts in near-term business trends, with positive revisions suggesting optimism about the business outlook [4] - The Zacks Rank system, which incorporates these estimate changes, currently assigns Medpace a rank of 2 (Buy) [6] Valuation Metrics - Medpace has a Forward P/E ratio of 38.45, which is a premium compared to the industry average Forward P/E of 15.5 [7] - The company also has a PEG ratio of 2.15, compared to the Medical Services industry's average PEG ratio of 1.72 [7] Industry Context - The Medical Services industry, which includes Medpace, has a Zacks Industry Rank of 165, placing it in the bottom 34% of over 250 industries [8] - Historically, the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a stock increase of +1.96% to $8.31, outperforming the S&P 500's daily loss of 0.74% [1] - Over the past month, the company's shares have declined by 5.12%, which is worse than the Medical sector's loss of 0.8% and the S&P 500's gain of 0.79% [1] Upcoming Earnings - The upcoming earnings release is anticipated to show an EPS of -$1.8, reflecting a 1.1% increase from the same quarter last year [2] - Revenue is forecasted at $37 million, indicating a 15.62% decrease compared to the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at -$5.94 per share, representing a 42.66% increase from the previous year [3] - Revenue for the fiscal year is estimated at $173 million, showing a 23.8% decline from the prior year [3] Analyst Estimates - Recent changes in analyst estimates for Ginkgo Bioworks are crucial as they reflect the evolving business trends [4] - Positive revisions in estimates are seen as indicators of analysts' confidence in the company's performance and profit potential [4] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently places Ginkgo Bioworks at 3 (Hold) [6] - The Medical - Biomedical and Genetics industry, which includes Ginkgo Bioworks, holds a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [7]

Quanta Services (PWR) closed the most recent trading day at $422.06, moving -1.57% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.74%. At the same time, the Dow lost 0.63%, and the tech-heavy Nasdaq lost 0.76%. The stock of specialty contractor for utility and energy companies has fallen by 5.7% in the past month, lagging the Construction sector's loss of 2.42% and the S&P 500's gain of 0.79%.Investors will be eagerly watching for the performance of Quanta ...